PROGEN.ST STO
Prostatype Genomics AB (publ)
1W: -22.6%
1M: -35.6%
3M: -57.3%
YTD: -92.4%
1Y: -86.5%
3Y: -100.0%
5Y: -100.0%
kr 0.09 ($0.01)
+0.00 (+0.00%)
Weekly Expected Move ±15.2%
kr 0
kr 0
kr 0
kr 0
kr 0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Smart Money Score
No convergence signal
Key Statistics
Market Capkr 3.1M ($0.3M)
52W Range0.088-2.28
Volume9,136,840
Avg Volume5,306,081
Beta1.40
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOFredrik Rickman
Employees7
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2020-11-03
Websiteprostatypegenomics.com
Augustendalsvägen 20
Nacka Strand 131 52
SE
Nacka Strand 131 52
SE
46 08 20 87 00
About Prostatype Genomics AB (publ)
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
Latest News
No recent news
Recent Insider Trades
No insider trades found